Cost-effectiveness analysis of penpulimab combined with paclitaxel and carboplatin as a first-line treatment for metastatic squamous non-small cell lung cancer in China
Objectives Penpulimab is a novel programmed death-1 (PD-1) inhibitor that has been approved in China for use in combination with chemotherapy as a first-line treatment for locally advanced or metastatic squamous non-small cell lung cancer (sq-NSCLC). However, the cost-effectiveness of this treatment...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-03-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/15/3/e091650.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850235910976700416 |
|---|---|
| author | Yuan Gao Liangxiao Wang Na Lv Chunyan Yan Xuechen Huo Ruigang Diao |
| author_facet | Yuan Gao Liangxiao Wang Na Lv Chunyan Yan Xuechen Huo Ruigang Diao |
| author_sort | Yuan Gao |
| collection | DOAJ |
| description | Objectives Penpulimab is a novel programmed death-1 (PD-1) inhibitor that has been approved in China for use in combination with chemotherapy as a first-line treatment for locally advanced or metastatic squamous non-small cell lung cancer (sq-NSCLC). However, the cost-effectiveness of this treatment in China remains to be determined. In this study, we aimed to assess the cost-effectiveness of penpulimab combined with paclitaxel and carboplatin for metastatic sq-NSCLC.Design Based on the AK105-302 trial (NCT03866993), a Markov model was created to evaluate the disease progression of metastatic sq-NSCLC patients over 10 years. The model included progression-free survival, progressive disease and death. The utility values were derived from published literature. Sensitivity studies were used to assess the robustness of the model outputs.Setting The Chinese healthcare system perspective.Participants A hypothetical Chinese cohort of patients with locally advanced or metastatic sq-NSCLC.Interventions Penpulimab plus chemotherapy versus chemotherapy.Primary outcome measure Costs, quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER).Results Compared with the chemotherapy alone group, the cost of penpulimab plus chemotherapy increased by US$3717.72, with an increase of 0.43 QALYs. The ICER was US$8625.78/QALY, which was well below the willingness-to-pay threshold of US$38 052/QALY. This demonstrated higher cost-effectiveness benefits, as confirmed by the sensitivity analysis results.Conclusions Under the Chinese health system, penpulimab plus paclitaxel and carboplatin is cost-effective for metastatic sq-NSCLC patients and can be used as an economical and effective treatment option. |
| format | Article |
| id | doaj-art-1127229c2f7a400eb80af3c83b14d44a |
| institution | OA Journals |
| issn | 2044-6055 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-1127229c2f7a400eb80af3c83b14d44a2025-08-20T02:02:06ZengBMJ Publishing GroupBMJ Open2044-60552025-03-0115310.1136/bmjopen-2024-091650Cost-effectiveness analysis of penpulimab combined with paclitaxel and carboplatin as a first-line treatment for metastatic squamous non-small cell lung cancer in ChinaYuan Gao0Liangxiao Wang1Na Lv2Chunyan Yan3Xuechen Huo4Ruigang Diao5Department of Pharmacy, Yantai Yuhuangding Hospital, Yantai, Shandong, ChinaDepartment of Pharmacy, Yantai Yuhuangding Hospital, Yantai, Shandong, ChinaDepartment of Pharmacy, Yantai Yuhuangding Hospital, Yantai, Shandong, ChinaDepartment of Pharmacy, Yantai Yuhuangding Hospital, Yantai, Shandong, ChinaDepartment of Pharmacy, Yantai Yuhuangding Hospital, Yantai, Shandong, ChinaDepartment of Pharmacy, Yantai Yuhuangding Hospital, Yantai, Shandong, ChinaObjectives Penpulimab is a novel programmed death-1 (PD-1) inhibitor that has been approved in China for use in combination with chemotherapy as a first-line treatment for locally advanced or metastatic squamous non-small cell lung cancer (sq-NSCLC). However, the cost-effectiveness of this treatment in China remains to be determined. In this study, we aimed to assess the cost-effectiveness of penpulimab combined with paclitaxel and carboplatin for metastatic sq-NSCLC.Design Based on the AK105-302 trial (NCT03866993), a Markov model was created to evaluate the disease progression of metastatic sq-NSCLC patients over 10 years. The model included progression-free survival, progressive disease and death. The utility values were derived from published literature. Sensitivity studies were used to assess the robustness of the model outputs.Setting The Chinese healthcare system perspective.Participants A hypothetical Chinese cohort of patients with locally advanced or metastatic sq-NSCLC.Interventions Penpulimab plus chemotherapy versus chemotherapy.Primary outcome measure Costs, quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER).Results Compared with the chemotherapy alone group, the cost of penpulimab plus chemotherapy increased by US$3717.72, with an increase of 0.43 QALYs. The ICER was US$8625.78/QALY, which was well below the willingness-to-pay threshold of US$38 052/QALY. This demonstrated higher cost-effectiveness benefits, as confirmed by the sensitivity analysis results.Conclusions Under the Chinese health system, penpulimab plus paclitaxel and carboplatin is cost-effective for metastatic sq-NSCLC patients and can be used as an economical and effective treatment option.https://bmjopen.bmj.com/content/15/3/e091650.full |
| spellingShingle | Yuan Gao Liangxiao Wang Na Lv Chunyan Yan Xuechen Huo Ruigang Diao Cost-effectiveness analysis of penpulimab combined with paclitaxel and carboplatin as a first-line treatment for metastatic squamous non-small cell lung cancer in China BMJ Open |
| title | Cost-effectiveness analysis of penpulimab combined with paclitaxel and carboplatin as a first-line treatment for metastatic squamous non-small cell lung cancer in China |
| title_full | Cost-effectiveness analysis of penpulimab combined with paclitaxel and carboplatin as a first-line treatment for metastatic squamous non-small cell lung cancer in China |
| title_fullStr | Cost-effectiveness analysis of penpulimab combined with paclitaxel and carboplatin as a first-line treatment for metastatic squamous non-small cell lung cancer in China |
| title_full_unstemmed | Cost-effectiveness analysis of penpulimab combined with paclitaxel and carboplatin as a first-line treatment for metastatic squamous non-small cell lung cancer in China |
| title_short | Cost-effectiveness analysis of penpulimab combined with paclitaxel and carboplatin as a first-line treatment for metastatic squamous non-small cell lung cancer in China |
| title_sort | cost effectiveness analysis of penpulimab combined with paclitaxel and carboplatin as a first line treatment for metastatic squamous non small cell lung cancer in china |
| url | https://bmjopen.bmj.com/content/15/3/e091650.full |
| work_keys_str_mv | AT yuangao costeffectivenessanalysisofpenpulimabcombinedwithpaclitaxelandcarboplatinasafirstlinetreatmentformetastaticsquamousnonsmallcelllungcancerinchina AT liangxiaowang costeffectivenessanalysisofpenpulimabcombinedwithpaclitaxelandcarboplatinasafirstlinetreatmentformetastaticsquamousnonsmallcelllungcancerinchina AT nalv costeffectivenessanalysisofpenpulimabcombinedwithpaclitaxelandcarboplatinasafirstlinetreatmentformetastaticsquamousnonsmallcelllungcancerinchina AT chunyanyan costeffectivenessanalysisofpenpulimabcombinedwithpaclitaxelandcarboplatinasafirstlinetreatmentformetastaticsquamousnonsmallcelllungcancerinchina AT xuechenhuo costeffectivenessanalysisofpenpulimabcombinedwithpaclitaxelandcarboplatinasafirstlinetreatmentformetastaticsquamousnonsmallcelllungcancerinchina AT ruigangdiao costeffectivenessanalysisofpenpulimabcombinedwithpaclitaxelandcarboplatinasafirstlinetreatmentformetastaticsquamousnonsmallcelllungcancerinchina |